Abstract
Section II of this Note will discuss Canada's prescription drug pricing scheme and why prescription drugs cost significantly more in the United States. Section III will discuss PhRMA v. Concannon, in cluding an analysis of the parties' arguments on price controls for pre- scription drugs. Section IV will illustrate that Washington's current role in the battle on prescription drug pricing is inadequate to provide accessible and affordable prescription drugs for its citizens. Section V concludes with the proposal that Washington adopt new legislation modeled after the Maine Act to Establish Fairer Pricing for Prescription Drugs, which created the Maine Rx Program. In this manner, Washington would have a better methodology to make prescription drugs more affordable within its borders so that more citizens will have access to necessary treatments without having to travel into Canada in order to purchase less expensive prescription drugs.
Recommended Citation
Shawna Lydon Woodward, Will Price Control Legislation Satisfactorily Address the Issue of High Prescription Drug Prices?: Several States Are Waiting in the Balance for PhRMA v. Concannon, 26 SEATTLE U. L. REV. 169 (2002).
